The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to the summary of product characteristics (SmPC) and to access overall treatment safety and quality of life assessed on multiple scales.

Start Date14 Nov 2023

Sponsor / Collaborator

Almirall SA

CTRI/2023/06/053784 / CompletedPhase 3

A Single-Arm, Multi-Centric Study to Evaluate Efficacy, Safety and Immunogenicity of Tildrakizumab in Patients With Moderate-to-Severe Plaque Psoriasis

Start Date18 Jun 2023

Sponsor / Collaborator

Sun Pharmaceutical Industries Ltd.

JPRN-jRCT2031220622 / RecruitingPhase 3

An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis

Start Date14 Mar 2023

Sponsor / Collaborator-

100 Clinical Results associated with Tildrakizumab-ASMN

100 Translational Medicine associated with Tildrakizumab-ASMN

100 Patents (Medical) associated with Tildrakizumab-ASMN

241

Literatures (Medical) associated with Tildrakizumab-ASMN

31 Dec 2024·The Journal of dermatological treatment

The effect of tildrakizumab on adipokines production in patients affected by psoriasis and obesity: preliminary results from a single center real-life study

Article

Author: Salza, Emanuela ; Caiazzo, Giuseppina ; Potestio, Luca ; Cacciapuoti, Sara ; Megna, Matteo

01 Mar 2024·The Annals of pharmacotherapy

Choosing Systemic Agents for Psoriasis

Author: Kontzias, Christina ; Feldman, Steven R ; Chandy, Rithi

Treatment options for moderate-to-severe psoriasis depend on drug efficacy and safety, patient preferences, comorbidities, and cost—no drug dominates across all dimensions. Interleukin (IL)-17 inhibitors may be preferred for fast-acting treatment, while the 3-month schedule of risankizumab, ustekinumab, or tildrakizumab may be attractive for patients who prioritize fewer injections. Phototherapy is suitable for patients who wish to avoid systemic agents or when cost is a concern. For patients with poor adherence, infliximab or tildrakizumab may be well suited as they require in-office administration. Dermatologists can educate patients on available therapies to find a regimen best suited to their needs.

25 Jan 2024·Clinical and experimental dermatology

Rapid response of erythrodermic pityriasis rubra pilaris to tildrakizumab

Article

Author: Lasa Elgezua, Olatz ; Villa-Gonzalez, Jose Maria ; Gonzalez-Hermosa, Maria Rosario ; Ratón Nieto, Juan Antonio ; Atxutegi-Ayesta, Xabier ; Gardeazabal García, Jesús

The cases of two patients with erythrodermic pityriasis rubra pilaris that showed a rapid and virtually complete response to tildrakizumab are presented. Treatment of pityriasis rubra pilaris remains challenging and there is very little evidence about use of interleukin-23 blockers in this condition. These cases may contribute to extending the available therapeutic options, especially when a fast clearance of the lesions is needed.

News (Medical) associated with Tildrakizumab-ASMN

28 May 2024

·firstwordpharma.com

Innovent preps for Chinese filing after picankibart shines in psoriasis study

Innovent Biologics will seek approval in China for its psoriasis candidate picankibart (IBI112) following positive findings from a registrational study. The anti-IL-23p19 antibody met the primary and key secondary endpoints of the Phase III CLEAR-1 study in Chinese patients with moderate-to-severe plaque psoriasis.The trial enrolled 500 patients who were randomly assigned to either placebo or picankibart 200mg every four weeks at week 0, 4 and 8 followed by 200mg or 100mg every 12 weeks. Co-primary endpoints included the proportion of participants achieving a ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) and those attaining a static Physician's Global Assessment (sPGA) score of clear (0) or almost clear (1) at week 16. Efficacy onset and maintenanceResults announced Monday showed that 80.3% of picankibart-treated participants achieved PASI 90 and 93.5% achieved sPGA 0 or 1 at week 16, significantly higher than the 2.0% and 13.1% of those receiving placebo, respectively. Moreover, the company also noted sustained skin clearance for picankibart, with 84.9% and 85.9% of participants on the 200mg dose every 12 weeks achieving PASI 90 and sPGA 0 or 1, respectively, at the one-year mark.Principal investigator Yulin Shi highlighted picankibart’s “short-term onset and long-term maintenance of efficacy,” alongside improved “convenience and adherence” offered by the every-12-week dosing regimen.Picankibart also demonstrated superiority over placebo on key secondary endpoints, including other measures of psoriasis severity and quality of life. The antibody showed a favourable safety profile as well, with no new safety signals identified. “There is no IL-23p19 target drug independently developed by Chinese enterprises in the domestic market,” remarked Lei Qian, vice president of clinical development at Innovent, adding that picankibart administered five or six times a year could offer “convenience value as a new treatment option compared to the current…drugs (7-16 times per year).”Other biologics targeting IL-23p19 in moderate-to-severe plaque psoriasis include Johnson & Johnson’s Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab), and AbbVie’s Skyrizi (risankizumab).

Clinical ResultPhase 3Phase 2

01 Apr 2024

·www.biospace.com

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria WILMINGTON, Del. and HONG KONG--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq:INCY) (“Incyte”) and China Medical Systems Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory. Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory. CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia. “We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “There remains a significant need for new, innovative treatment for vitiligo and other immune-mediated dermatologic conditions, and we look forward to working together with the CMS team to bringing these products to market in China.” Mr. Huang Anjun, the general manager of CMS Skinhealth, stated that, “We expect that this collaboration will enhance CMS Skinhealth's portfolio of potential treatments for vitiligo that, if approved, will provide differentiated treatment options for vitiligo patients in China. Upon approval, povorcitinib is poised to synergize with the innovative drugs in the commercialization stage of our pipeline Ilumetri (tildrakizumab injection), original/drugs including Hirudoid (mucopolysaccharide polysulfate cream) and Aethoxysklerol (polidocanol injection) in terms of our network and market resources, which will help the Product to realize its clinical and commercial value.” The transaction is effective immediately upon the execution of the Collaboration and License Agreement. About Povorcitinib Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo and HS in multiple countries outside of China. Additionally, Phase 2 clinical studies of povorcitinib for PN, asthma and chronic spontaneous urticaria are also ongoing. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. Overactivity of the JAK signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of vitiligo. It is estimated that there are approximately 14 million vitiligo patients in China and 6.5 million in the eleven Southeast Asian countries respectively. Non-segmental vitiligo patients account for approximately 85% of them1. Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 302. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. About Hidradenitis Suppurativa (HS) HS is a chronic recurrent inflammatory skin condition characterized by the presence of painful inflammatory nodules, abscesses, ruptures, as well as the formation of sinus tracts and scarring. Overactivity of the JAK signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of HS3. It is estimated that there are approximately 470 thousand HS patients in China, about 75% of whom are moderate to severe patients4. Additionally, it is estimated that there are approximately 13 thousand HS patients in the six Southeast Asian countries, comprising Thailand, Singapore, Malaysia, Philippine, Vietnam and Indonesia. HS has been included in the second batch of the Rare Disease List in China. Given the debilitating nature of condition, it can have a profoundly negative effect on patients’ quality of life. However, currently in China, there are no biologics or small molecule medicines approved by the National Medical Products Administration for the treatment of HS, creating an urgent need for effective therapeutic options5. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. About CMS Skinhealth CMS’s Dermatology and Medical Aesthetic Business "CMS Skinhealth" regards dermatology prescription products as its core, and extends to dermatology-grade skincare products and light medical aesthetic products, continually optimizing full lifecycle skin-health management solutions, and gradually moving toward becoming "the largest and most professional skin-health management company in China ". Relying on its strong clinical development and commercialization advantages, CMS will realize the commercialization of povorcitinib in the Territory as soon as possible to meet the clinical needs of oral vitiligo drugs with efficacy and benefit relevant patients. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding whether and when povorcitinib will be approved for use in mainland China, Hong Kong, Macau, Taiwan or Southeast Asia; whether and when CMS will bring povorcitinib to market in mainland China, Hong Kong, Macau, Taiwan or Southeast Asia; the potential of povorcitinib to treat patients with vitiligo, hidradenitis superativa or for any other indication; the potential for Incyte to receive royalties and payments from CMS for development and commercial milestones; and the potential for Incyte to broaden its ability to bring new medicines to patients in Asia and elsewhere, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; Incyte’s dependence on its relationships with its collaboration partners; the efficacy or safety of Incyte’s products and the products of its collaboration partners; the acceptance of Incyte’s products and the products of its collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended December 31, 2023. Incyte disclaims any intent or obligation to update these forward-looking statements. CMS Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. This press release may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of or any omission from this press release is expressly excluded. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. The Group assumes no obligation to update any forward-looking information contained in this press release. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. References： Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015 Jul 4;386(9988):74-84. doi: 10.1016/S0140-6736(14)60763-7. Epub 2015 Jan 15. PMID: 25596811 Frisoli M, et al. Vitiligo: mechanisms of pathogenesis and treatment. Annu. Rev. Immunol. 2020;38(1):621-648 Solimani, F., Meier, K., & Ghoreschi, K. (2019). Emerging topical and systemic JAK inhibitors in dermatology. Frontiers in immunology, 10, 2847 Prevalence of Acne Inversa (Hidradenitis Suppurativa) in China: A Nationwide Cross-Sectional Epidemiological Study Diagnosis and treatment of acne inversa/hidradenitis suppurativa in China: an expert consensus statement（2021 version）

License out/inPhase 3Phase 2

14 Mar 2024

·www.prnewswire.com

Psoriasis in America - Insights into Psoriasis Patient Demographics, Quality of Life, Information-seeking Behaviors, HCP Engagement and Treatment Experiences

DUBLIN, March 14, 2024 /PRNewswire/ -- The "Psoriasis in America 2023: Understanding the Psoriasis Patient Experience" report has been added to ResearchAndMarkets.com's offering. Approximately 7.5 million people in the United States have psoriasis. This Psoriasis in America report provides a comprehensive look at life for those living with psoriasis. Using detailed quantitative data, it gives a full picture of the psoriasis patient experience - from symptoms to treatment to HCP relationships to quality of life - so you can make informed, strategic decisions, identify opportunities, and understand potential challenges. The report offers an in-depth look at the psoriasis patient experience. This large-scale, patient-reported data leverages vital quantitative insights essential to understanding key touchpoints in the psoriasis patient journey, including condition management, HCP engagement, quality of life, treatment experience and satisfaction, and much more. This report lifts the curtain on life with psoriasis, giving stakeholders an actionable look at the behaviors, attitudes, perceptions, needs, and experiences of people living with the condition. Data can be used to inform strategic decisions, including product communications, competitive assessments, concept development, landscape analyses, patient journey overlays, and forecasting inputs. This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost - please see the report following purchase for more information. The analyst reaches millions of people through its portfolio of 45+ condition-specific online health communities - including PlaquePsoriasis.com - to provide information, connection, and support to patients and caregivers in the U.S. This report includes a deep-dive into: Psoriasis patient demographics Age, gender, ethnicity, marital status, children, employment status, income, location, insurance, and other health conditions Impact of psoriasis on quality of life Severity, impact on quality of life, symptoms experienced, and what patients wish others better understood Information-seeking behaviors Information sources used, plus topics of interest HCP engagement Primary HCP seen for condition, satisfaction with HCP, and discussion about brands aware of/not used Psoriasis treatment awareness and experiences Aided awareness of specific treatments, treatment experience, satisfaction with current treatments, perceived control with current treatment plan, and interest/participation in clinical trials Key questions answered in this report: To what extent do people say psoriasis impacts their overall quality of life? What's the average number of flares in the past year? What do patients wish others understood about psoriasis? What percentage of patients see a specialist for psoriasis treatment? What treatments have the highest aided brand awareness among patients? What percentage of patients use a biologic? How many patients feel their psoriasis is well-controlled on their current treatment plan? What percentage of patients are likely to switch or add new treatments in the next six months? What medications have patients discussed with their HCP? What are the top online resources people with psoriasis use to find information? What kinds of content and information do patients search for? What percentage of patients search for information on treatment options? Methodology Psoriasis in America consists of: A 20-minute online quantitative survey, covering demographics, comorbidities, quality of life/impact, HCP interactions, as well as treatment awareness, experiences, and discussions Qualitative patient insights from open-ended responses Additional details: Fielded: January 16, 2023 to April 14, 2023 Convenience sample of 490 respondents diagnosed with psoriasis Respondents are age 18+, living in the U.S., and are recruited from proprietary online health communities and recruiting partners Key Topics Covered: Respondent Demographics Research Highlights Condition Status and Quality of Life Severity and Exacerbations Symptoms Experienced Impact on Quality of Life Qualitative Patient Insights Information-Seeking Behaviors Resources Used to Manage Health Types of Content/Information Sought Treatment Awareness and Experiences Primary HCP Seen for Psoriasis Care Aided Brand Awareness of Treatments Treatment Usage Condition Control on Current Treatment and Clinical Trial Interest Treatment Discussions with HCP Appendix with All Data Charts and Distributions Brands and treatments mentioned in this report include: Topical corticosteroid (such as hydrocortisone) BRYHALIT (halobetasol propionate) lotion DesOwen (desonide) SERNIVOT (betamethasone dipropionate) SORILUXT Foam (calcipotriene) TACLONEX (calcipotriene and betamethasone) TAZORAC (tazarotene) VECTICAL (calcitriol) VTAMA (tapinarof) ZITHRANOLT-RR (anthralin) ZORYVET (roflumilast) Acitretin (SORIATANE) ARAVA (leflunomide) Azathioprine (such as IMURAN, AZASAN) Cyclosporine (such as Sandimmune, NEORAL, RESTASIS) Methotrexate (eg, Rheumatrex), also sometimes given as an injection OTEZLA (apremilast) PLAQUENIL (hydroxychloroquine) RINVOQ (upadacitinib) SOTYKTUT (deucravacitinib) Sulfasalazine (Azulfidine) XELJANZ/XELJANZ XR (tofacitinib citrate) AMJEVITAT (adalimumab-atto) Hide until launched in US AVSOLA (infliximab-axxq) CIMZIA (certolizumab) COSENTYX (secukinumab) CYLTEZO (adalimumab-adbm) Hide until launched in US ENBREL (etanercept) ERELZIT (etanercept-szzs) Hide until launched in US HULIO (adalimumab-fkjp) Hide until launched in US HUMIRA (adalimumab) HYRIMOZ (adalimumab-adaz) Hide until launched in US ILUMYAT (tildrakizumab-asmn) INFLECTRA (infliximab-dyyb) IXIFIT (infliximab-qbtx) Hide until launched in US ORENCIA (abatacept) REMICADE (infliximab) RENFLEXIST (infliximab-abda) SIMPONI (golimumab) SIMPONI ARIA (golimumab for infusion) SILIQT (brodalumab) SKYRIZI (risankizumab-rzaa) STELARA (ustekinumab) TALTZ (ixekizumab) TREMFYA (guselkumab) For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 Deals associated with Tildrakizumab-ASMN

External Link

KEGG	Wiki	ATC	Drug Bank
-	Tildrakizumab-ASMN	L04AC	DB14004

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Plaque psoriasis	US	Sun Pharmaceutical Industries Ltd.	20 Mar 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Scalp Dermatoses	Phase 3	US	Sun Pharmaceutical Industries Ltd.	29 Mar 2019
Scalp Dermatoses	Phase 3	AU	Sun Pharmaceutical Industries Ltd.	29 Mar 2019
Arthritis, Psoriatic	Phase 3	AR	Sun Pharmaceutical Industries Ltd.	29 Aug 2018
Arthritis, Psoriatic	Phase 3	HU	Sun Pharmaceutical Industries Ltd.	29 Aug 2018
Arthritis, Psoriatic	Phase 3	MX	Sun Pharmaceutical Industries Ltd.	29 Aug 2018
Arthritis, Psoriatic	Phase 3	RU	Sun Pharmaceutical Industries Ltd.	29 Aug 2018
Arthritis, Psoriatic	Phase 3	UA	Sun Pharmaceutical Industries Ltd.	29 Aug 2018
Metastatic castration-resistant prostate cancer	Phase 2	CH	Sun Pharmaceutical Industries Ltd.	01 Dec 2020
Metastatic castration-resistant prostate cancer	Phase 2	GB	Sun Pharmaceutical Industries Ltd.	01 Dec 2020
Ankylosing Spondylitis	Phase 2	US	Sun Pharmaceutical Industries Ltd.	06 Nov 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04541329 (CTgov)	Phase 4	inflammatory dermatosis \| Psoriasis vulgaris	7	Tildrakizumab	ydxbgrbrvl(vxiewgxfwb) = ohehlgsxkg zpeasbmees (swfvrhthid, ienhuqevuh - mzkdmhvcis) View more	-	30 Apr 2024
NCT05108766 (Pubmed)	Phase 3	Plaque psoriasis	-	Tildrakizumab 100 mg	plyibbhstu(pxztpsehts) = mpzvyjuvjo colpvmpyfc (neinxqwfob, 73/110) View more	-	09 Jan 2024
NCT05108766 (Pubmed)	Phase 3	Plaque psoriasis	-	Placebo	plyibbhstu(pxztpsehts) = iyjyuyigql colpvmpyfc (neinxqwfob, 14/110) View more	-	09 Jan 2024
EADV2023	Not Applicable	SNPs	81	Tildrakizumab	oevgtmkyfx(vyontedrdq) = izqtnuemeh ubdqunvxku (dxilfastif ) View more	-	11 Oct 2023
EADV2023	Phase 4	Plaque psoriasis	177	Tildrakizumab 100 mg	uvmdgiddyk(zglwqlnptw) = a greater BSA affected at baseline could be argued nyvbfxsizs (uizefknkzc ) View more	Positive	11 Oct 2023
TILOT (EADV2023)	Not Applicable	Plaque psoriasis	503	Tildrakizumab 100 mg (s.c.)	xeohvigdfy(yrcgxjdakn) = yikcmtjdbw afhqqqkndo (hfcvsyllxf ) View more	Positive	11 Oct 2023
TILOT (EADV2023)	Not Applicable	Plaque psoriasis	503	Placebo	xeohvigdfy(yrcgxjdakn) = olzdwsersm afhqqqkndo (hfcvsyllxf ) View more	Positive	11 Oct 2023
EADV2023	Not Applicable	-	51	Tildrakizumab 100 mg	jfxkgohnyr(nwtvpapkkg) = no adverse event was reported by our patients during the whole 12-week follow-up period xibrwibqnw (lvtavuihff )	Positive	11 Oct 2023
WCD2023	Not Applicable	Psoriasis	129	Tildrakizumab	fxgmkhhdfx(geyxupgimq) = xteotvoopf oxtpbpcept (xmaeyattzz )	Positive	03 Jul 2023
TRIBUTE (WCD2023)	Phase 4	Plaque psoriasis	177	Tildrakizumab 100 mg	dexgcardli(gkxxdwrkya) = qzjeazmfjv xpdvngcmwn (nwmoszxfsb )	-	03 Jul 2023
POSITIVE (WCD2023)	Phase 4	-	263	Tildrakizumab	clqnluiydy(nxtwxjsmku) = At the point of this analysis, 8.7% of patients had ≥1 adverse event (AE). The most frequent AE (5 events) was COVID-19. No serious AEs related to tildrakizumab were reported. mcotbndrhx (jviwjysjqs )	Positive	03 Jul 2023
EULAR2023	Not Applicable	Psoriasis	-	Tildrakizumab	ewqdxieznq(abmcbyykci) = kwwbgroyjn ixdswesnmq (ycnirfziuh, -19.146 to -10.561)	-	31 May 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis